Anandamide Induced Anti-Convulsion in an *In Vitro* Model of Epilepsy

Abdulmonem A. Al Hayani, DipFMS, PhD

Department of Anatomy, Faculty of Medicine,
King Abdulaziz University, Jeddah, Saudi Arabia

Abstract. In both *in vitro* and *in vivo* models of epilepsy, cannabinoids had anti-convulsant properties, which have been shown to be mediated through activation of central cannabinoid type 1 (CB_1) receptors The current study used 24 adult Sprague-Dawely rats to investigate the effects of endogenously occurring cannabinoids (endocannabinoids) on epileptiform activity induced by picrotoxin. Extracellular recordings were made from stratum pyramidale of the CA_1 region of hippocampal slices maintained in a submersion type recording chamber. Stimulation with single pulses evoked population spikes of approximately equal amplitude. Using single pulse stimulation, perfusion of 0.5 μM picrotoxin caused a small increase in the amplitude of the first population spike, and caused epilepsy by introducing a second or multiple population spikes. In the presence of picrotoxin, anandamide reduced the amplitude of both the first population spike (PS1) and the second population spike (PS2), thus reducing the epilepsy. The CB_1 receptor antagonist, AM 281 (500 nM) had no effect on responses recorded in the presence of picrotoxin, but totally blocked the effect of subsequently perfused anandamide. The results showed that anandamide caused an anti-convulsion effect. Furthermore, these results implicate the cannabinoid CB_1 receptor as a major endogenous site of seizure modulation.

Keywords: Anandamide, Endogenous cannabinoids, Anti-convulsion, Hippocampal slice.

Introduction

Epilepsy is one of the most common neurological conditions and is characterised by spontaneous recurrent seizures[1]. Understanding the pathophysiology of seizure initiation and termination would have important implications for our ability to manage seizure disorders and for the potential development of novel anti-epileptic agents. Previous research in our laboratory[2] and others[3-5] have shown that cannabinoid compounds such as WIN55,212-2 are anti-epileptic compounds in both *in vitro* and *in vivo* studies. We further demonstrated that the anti-epileptic effect of cannabinoids was mediated through the central cannabinoid CB_1 receptors[2].

Two different cannabinoid (CB_1 and CB_2) receptors , have been identified, so far, which were cloned in 1990 and 1993, respectively[6]. CB_1 is the type preferentially expressed in the brain and is known to mediate the psychoactive effect of cannabinoids[7]. The distribution of CB_1 receptors is not homogenous in the brain, CB_1 receptors were found to be very abundant in the hippocampus, neocortical area, and the limbic system, the areas believed to modulate seizure activity[8]. The discovery of cannabinoid receptors was followed in 1992 and 1995 by the demonstration of the existence of endogenous cannabinoid receptor agonists[9]. The most important of these are arachidonylethanolamide synthase (anandamide synthase) and 2-arachidonylglycerol where there is evidence that both can serve as neuromodulators or neurotransmitters[10]. As our previous study has shown an anti-epileptic effect of the cannabinoid CB_1 agonist WIN55,212-2 2, the next logical step is to investigate the role of endogenous cannabinoids in the anti-epileptic scenario, which is the aim of the current study.

Materials and Methods

The study was conducted in the Department of Biomedical Sciences, Institute of Medical Sciences, Aberdeen University, Aberdeen, UK. Twenty-four young adult Sprague-Dawley rats aged from 5- to 7- weeks were used in the current study. After general anesthesia with halothane, they were sacrificed and the brain was removed from the skull and submerged in oxygenated cold (under 4°C) artificial cerebrospinal fluid (aCSF). The hippocampus was dissected out and chopped transversely on a McIIwain tissue chopper forming slices 400 μm thick. The slices were placed onto a moist filter paper in a Petri dish and maintained in a well-oxygenated and humidified chamber. After at least one hour, slices were transferred to a submersion-type recording chamber which was continuously perfused with aCSF at a rate of 1.5 ml/min. The temperature was maintained between 28-30°C. A bipolar stimulating electrode was used to stimulate the Schaffer collateral commissural fibres and evoked population spikes were recorded from the cell body layer of the CA1 region of the hippocampus

using a glass capillary microelectrode filled with 3M sodium chloride (NaCl). Half-maximal population spikes were then evoked at 30 second intervals until a stable baseline of at least 30 min was established. Data was stored and analysed using the LTP program[11].

Drugs were applied by addition to the perfusion medium. Stock solutions of the endocannabinoid CB_1 receptor agonists (anandamide) were made up in alcohol and stored at 4˚C. When required they were mixed with Tween 80 (two parts Tween 80 to one part of anandamide) and the ethanol was evaporated by using steam of nitrogen gas. Saline was then added in aliquots of 0.05 ml and the solution diluted with aCSF to obtain the required concentration. AM281 (the cannabinoid CB_1 receptor antagonist) was made up as a 10 mM stock solution in dimethyl sulfoxide (DMSO) and diluted in aCSF as required.

Epilepsy was induced by using the convulsant poisonous plant derivative 'picrotoxin', which is a non-competitive GABAA receptor antagonist. Picrotoxin has been widely used to induce epilepsy in the *in vitro* preparations[12]. The response recorded after the application of picrotoxin showed multiple population spikes which could be named as PS1, PS2, *etc*…(Fig. 1).


FIG. 1. An example of a synaptic response recorded from the CA1 region of the hippocampal slice showing multiple population spikes after application of picrotoxin (500 nM). OS1 is the first population spike and the upward arrow indicates the amplitude (height) of the population spike in millivolt (mV). OS2 is the second population spike and the upward arrow indicates the amplitude (height) of the population spike in mV. Inset shows the time scale of the synaptic response.

In all cases, statistical analysis was performed using the INSTAT program to measure significance using the paired "Student's" *t* test (*t* test). Each slice included in the results came from a different rat. A *P* value of less than 0.05 was considered statistically significant. Anandamide, Tween 80 and AM281 were obtained from Tocris (Bristol, UK).

Results

1. Picrotoxin induced convulsions in the rat hippocampal slice: After recording a steady baseline for at least 30 minutes, perfusion of picrotoxin (500 nM) for 30 min caused epilepsy by introducing a second population spike (PS2) and increasing the amplitude of the first population spike (PS1) from the mean baseline value of $64.3 \pm 5\%$ to $78.5 \pm 3\%$ (n=5, Fig. 2).

2. Anandamide is an anticonvulsant in the *in vitro* model of epilepsy: After a steady baseline has been recorded for at least 30 minutes, picrotoxin (500 nM) was perfused until a PS2 was introduced and had reached a steady baseline. The perfusion of picrotoxin increased the amplitudes of PS1 and PS2. Anandamide (10 μM) was then perfused for 30 min. Perfusion of anandamide (10 μM) reduced the amplitude of PS1 to $53.4 \pm 7\%$ of the picrotoxin baseline. The amplitude of PS2 was reduced to $42.6 \pm 6\%$ of the picrotoxin baseline (n=8, Fig. 2). Anandamide therefore showed a strong anticonvulsant effect.

(A)

(B)

FIG. 2. Perfusion of anandamide (10 μM) for 30 minutes caused a significant reduction ($P<0.05$) of the amplitude of PS1 (A) and PS2 (B) in slices where epileptiform activity had been induced by perfusion of picrotoxin (500 nM). Data were presented as mean amplitude (% of picrotoxin baseline).

3. Anandamide's anticonvulsant effect is mediated by cannabinoid's CB_1 receptor activation: A pre-treatment dose of the cannabinoid CB_1 receptor antagonist, AM 281 (500 nM) was used to test if the effect of anandamide was mediated through the central cannabinoid CB_1 receptors or not. Stable control response was obtained prior to the perfusion of 500 nM picrotoxin. Once a stable PS2 was obtained, the CB_1 receptor antagonist AM 281 (500 nM) was perfused for 30 min. This was followed by a perfusion of anandamide (10 μM) for 30 min. AM 281 alone did not affect the amplitude of the PS1 and PS2. After 30 min perfusion of AM 281, the amplitude of PS1 was $95 \pm 4\%$ of the picrotoxin baseline (*i.e.*, no significant change). AM 281 markedly reduced the effect of the subsequently perfused anandamide (10 μM). The perfusion of anandamide (10 μM) for 30 min resulted in a very small reduction of the amplitudes of PS1 and PS2 ($94 \pm 8\%$ and $92 \pm 9\%$, respectively) which were not statistically significant (n=6, p < 0.05, Fig. 3).


FIG. 3. Perfusion of CB_1 receptor antagonist AM 281 (500 nM) for 30 min had no significant effect ($P < 0.05$) on the amplitude of PS1 (A) and PS2 (B) in slices where epileptiform activity had been induced by perfusion of picrotoxin (500 nM). However, AM 281 totally blocked the effect of subsequently perfused anandamide (10 μM) for 30 min. Data were presented as mean amplitude (% of picrotoxin baseline).

4. The effect of anadamide was not due to the drug vehicle Tween 80: The drug vehicle Tween 80, used to disperse anandamide, had no effect on population spikes. Perfusion of Tween 80 alone for 30 min at a concentration equivalent to that used to disperse 10 µM anandamide had no effect on either the amplitude of PS1 or the amplitude of PS2. After 30 min of Tween 80 perfusion, the amplitudes of PS1 and PS2 were $98 \pm 11\%$ and $102 \pm 6\%$ of the original baseline respectively (n=5, p<0.05, Fig. 4).


(A)

(B)

Fɪɢ. 4. Perfusion of the drug vehicle Tween 80, used to disperse anandamide, for 30 min has no significant effect ($P < 0.05$) on the amplitude of PS1 (A) and PS2(B) in slices where epileptiform activity had been induced by perfusion of picrotoxin (500 nM). Data were presented as mean amplitude (% of picrotoxin baseline).

Discussion

The results of the current study demonstrate that anandamide, an endogenous cannabinoid, is a potent anticonvulsant in an *in vitro* model. The data also demonstrate that this anticonvulsant effect is mediated by activation of the cannabinoid CB_1 receptor.

Anandamide was the first putative endogenous ligand for cannabinoid receptors to be identified[13], therefore attention has focussed on whether anandamide may also act physiologically to induce some useful medical effects. Anandamide is an eicosanoid that belongs to a class of fatty-acid derivatives of N-arachidonyl-phosphatidylethanolamine. The compound is reported to be synthesized ''on-demand'' by phospholipase-D in a depolarization and calcium-dependent manner[14]. Previous researchers have shown that elevated intracellular calcium accompanies seizure activity[15]. The depolarization and calcium dependent synthesis of these compounds, therefore, suggests that the endogenous cannabinoid system plays a compensatory role in dampening seizure activity. Moreover, high concentrations of anandamide are detected in hippocampus an area with high cannabinoid CB_1 receptor expression[16]. The hippocampus is known to be a major brain region involved in epileptogenesis and seizure disorders[17]. Thus, endocannabinoids are likely to play an important role in modulating seizure threshold and severity.

Apart from its role in epileptogenesis, anandamide was also found to exert intense emotional and cognitive effects. Cerebrospinal anandamide levels were found to be elevated in acute schizophrenia and were inversely correlated with psychotic symptoms[18].

Anandamide mediates their effects by binding to cannabinoid CB_1 and CB_2 receptor[19]. However, it is unlikely that the cannabinoid CB_2 receptor mediates the anticonvulsant effect of anandamide because this receptor is not present in brain[20]. Moreover, the CB_1 receptor antagonist (AM 281) has been shown to be selective for the cannabinoid CB_1 receptor, with negligible binding at cannabinoid CB_2[6]. Anandamide can also bind vanilloid receptors 1 (VR1) that are found in the brain[21]. However, it is unlikely that the vanilloid VR1 receptor is anandamide's anticonvulsant site of action because the selective cannabinoid CB_1 receptor antagonist AM 281 completely blocks the anticonvulsant effect of anandamide. Thus, the current data strongly implicate the cannabinoid CB_1 receptor as the mechanistic site of action mediating the anticonvulsant effects of endocannabinoids.

Due to the highly lipophilic nature of the majority of endocannabinoids, solubility problems have been encountered during experiments, which have only been overcome by the use of a dispersing vehicle such as Tween 80, ethanol or DMSO. Tween 80 was chosen for the current study following the example of many previous studies[2,3,21]. The anti-convulsant effect of anandamide in the current study was not due to the effect of the drug vehicle Tween 80, which was used to disperse the lipophilic anandamide. Application of Tween 80 at a concentration equivalent to that used to disperse anandamide (10 µM) had no significant effect on either the amplitude of the PS1 or PS2.

The current study provides direct evidence for a physiological role of endo-cannabinoids in modulating convulsion. In addition, these data further establish the cannabinoid CB_1 receptor and the endogenous cannabinoid system as a potential treatment target for the control of epilepsy. Additional studies investigating the role of this system in epilepsy are clearly warranted.

References

[1] **Shorvon SD**. Epidemiology, classification, natural history, and genetics of epilepsy. *Lancet* 1990; **336(8707)**: 93-96.

[2] **Al-Hayani A**. Cannabinoids as an anti-convulsant drugs. *Al Azhar Med J* 2003: **32**: 227-236.

[3] **Ameri A, Wilhelm A, Simmet T**. Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. *Br J Pharmacol* 1999; **126(8)**: 1831-1839.

[4] **Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ.** Assessment of the role of CB_1 receptors in cannabinoid anticonvulsant effects. *Eur J Pharmacol* 2001; **428(1)**: 51-57.

[5] **Wallace MJ, Martin BR, DeLorenzo RJ.** Evidence for a physiological role of endo-cannabinoids in the modulation of seizure threshold and severity. *Eur J Pharmacol* 2002; **452(3)**: 295-301.

[6] **Pertwee RG.** Pharmacology of cannabinoid CB_1 and CB_2 receptors. *Pharmacol Ther* 1997; **74(2)**: 129-180.

[7] **Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI.** Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 1990; **346(6284)**: 561-564.

[8] **Pertwee RG.** The evidence for the existence of cannabinoid receptors. *Gen Pharmacol* 1993: **24**: 811-824.

[9] **Di Marzo V, Melck D, Bisogno T, De Petrocellis L.** Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. *Trends Neurosci* 1998; **21(12)**: 521-8. Review. Erratum in: *Trends Neurosci* 1999; **22(2)**: 80.

[10] **Pertwee RG.** Cannabinoid receptors and pain. *Prog Neurobiol* 2001; **63(5)**: 569-611. Review.

[11] **Anderson W, Collingridge G.** A data acquisition program for on-line analysis of long-term potentiation and long-term depression. *Soc Neurosci Abst* 1996; **23**: 665. (www.LTP-program.com).

[12] **Paton GS, Pertwee RG, Davies SN.** Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. *Neuropharmacology* 1998; **37(9)**: 1123-1130.

[13] **Szallasi A, Di Marzo V.** New perspectives on enigmatic vanilloid receptors. *Trends Neurosci* 2000; **23(10)**: 491-497.

[14] **Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D.** Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature* 1994; **372(6507)**: 686-691.

[15] **Limbrick DD Jr, Pal S, DeLorenzo RJ.** Hippocampal neurons exhibit both persistent Ca^{+2} influx and impairment of Ca^{+2} sequestration/extrusion mechanisms following excitotoxic glutamate exposure. *Brain Res* 2001; **894(1)**: 56-67.

[16] **Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, Becker GW.** Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. *FEBS Lett* 1996; **393(2-3)**: 231-235.

[17] **Lothman EW, Bertram EH 3rd, Stringer JL.** Functional anatomy of hippocampal seizures. *Prog Neurobiol* 1991; **37(1)**: 1-82.

[18] **Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D.** Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. *Neuropsychopharmacology* 2004; **29(11)**: 2108-2114.

[19] **Howlett AC.** Pharmacology of cannabinoid receptors. *Annu Rev Pharmacol Toxicol* 1995; **35**: 607-634.

[20] **Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z**. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. *J Biol Chem* 1996; **271(17)**: 9902-9905.

[21] **Al-Hayani A, Wease KN, Ross RA, Pertwee RG, Davies SN.** The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. *Neuropharmacology* 2001; **41(8)**: 1000-1005.

مـادة الأنانداميد تقلّـل من التشنجات الصرعية في التجارب على الشرائح المخية

عبدالمنعم عبدالسلام الحياني

قسم التشريح ، كلية الطب ، جامعة الملك عبدالعزيز ،
جـــــدة – المملكة العربية السعودية

المستخلص.   لقد أثبتت مستخلصات الكانابينويدز المصنعة قدرتها الفائقة على تقليل التشنجات الصرعية سواءً في الدراسات التي تستخدم شرائح مخية أو حيوانات كاملة ، وذلك عن طريق تحفيز مستقبلات (س ب ١) العصبية . ولمعرفة إذا كانت مستخلصات الكانابينويدزالمفرزة داخل الجسم لها نفس التأثير فقد استخدمت الدراسة الحالية ٢٤ فأرًا أبيضًا لدراسة تاثير هذه المواد أيضًا على التشنجات الصرعية. ولاختيار تأثير هذه المواد على التشنجات الصرعية ، تم استئصال الهيبوكامبس من مخ الفأر الأبيض وتم تقطيعه إلى شرائح بسمك ٤٠٠ مايكرون ، وذلك لدراستها بالوسائل الكهروفسيولوجية ، والتي تم من خلالها تسجيل الاستجابة العصبية قبل وبعد إضافة الأدوية المختلفة . كما تم قياس طول الاستجابة العصبية والتغيّر فيها قبل وبعد إضافة الأدوية المختلفة. و قد تم تحليل النتائج باستخدام برنامج « إل تي بي ».

بعد إحداث تشنجات صرعية عن طريق إضافة مادة البكروتوكسين إلى الشرائح المخية ، تمت إضافة مادة الأنانداميد، والتي قامت بتقليل التشنجات الصرعية بشكل ملحوظ ومهم إحصائيا. وعند إضافة مادة «إيه إم ٢٨١» لم تتمكن مادة الأنانداميد من منع حدوث التشنجات الصرعية. لقد أثبتت الدراسة الحالية قدرة الأنانداميد على تقليل التشنجات الصرعية بشكل مهم وملحوظ ، مما يدلل على الدور الكبير والمهم الذي تلعبه مستقبلات (س ب ١) العصبية في منع حدوث الصرع.